From 2023 to 2033, the global digital breast tomosynthesis (DBT) equipment market is projected to develop at a CAGR of 13.9%, reaching an estimated value of US$ 2,594.4 million. By 2033, the digital breast tomosynthesis (DBT) equipment market size is expected to attain US$ 9,495.1 million.
The digital breast tomosynthesis (DBT) equipment market expansion is correlated with the prevalence of breast cancer and the rising need for breast cancer screening and diagnosis. A cutting-edge technology called digital breast tomosynthesis or 3D breast tomosynthesis enables radiologists to diagnose breast cancer accurately.
Through computer reconstruction, a succession of 2-D photographs is used to produce a 3-D image of the women's breasts. Due to the high rate of accuracy it offers for diagnosing breast cancer in women with dense breasts, this technology is often used. Digital breast tomosynthesis has a significantly lower chance of producing incorrect results than traditional mammography, which creates 2-D digital images of the breast.
It is crucial to efficiently complete the diagnostic and screening because the incidence is fairly high, which may enhance the standard of patient care. This is very beneficial for the digital breast tomosynthesis (DBT) equipment market.
Key Highlights of the Digital Breast Tomosynthesis (DBT) Equipment Industry
| Attributes | Details |
|---|---|
| DBT Equipment Market Value for 2023 | US$ 2,594.4 million |
| DBT Equipment Market Value for 2033 | US$ 9,495.1 million |
| DBT Equipment Market CAGR from 2023 to 2033 | 13.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The digital breast tomosynthesis (DBT) equipment market surged strongly, with a phenomenal 15.9% CAGR between 2018 and 2022. Early identification of breast cancer improves patients' prognosis and treatment effectiveness. The goal of numerous campaigns to increase knowledge about breast cancer and encourage early diagnosis at the national, regional, and local levels is to be led by governmental authorities, public organizations, business corporations, advocacy groups, and community organizations.
| Historical CAGR | 15.9% |
|---|---|
| Forecast CAGR | 13.9% |
Another motivating factor is technology, which has improved sensitivity and specificity in detecting breast cancer by lowering false positives and negatives and false negatives. Combining 2-D and 3-D mammography enables a thorough examination that helps find hidden breast tumors.
Given these elements, a solid 14.1% CAGR is anticipated for the global digital breast tomosynthesis (DBT) equipment market from 2023 to 2033, exhibiting significant growth opportunities.
The cancer industry also requires several technological improvements to keep up with the general healthcare business. Tomosynthesis is the only imaging technology to visualize the entire breast and detect the total radiation dosage, patient movements, image time, detector motion, and detector performance. It also has a comprehensive future biopsy capability for the lesions driving the breast tomosynthesis equipment market.
Principal Consultant
The high equipment cost limits market expansion, particularly in developing nations. For various types and manufacturers, digital breast tomosynthesis equipment costs vary.
Priced between US$ 1,40,000 and US$ 2,75,000, the 3D models of Hologic Inc. and GE Healthcare's high-end equipment are available. The expensive cost of breast tomosynthesis equipment is a key problem for patients; it prevents healthcare practitioners from installing such equipment and leads to laborious diagnostic procedures. Due to these circumstances, the digital breast tomosynthesis (DBT) equipment market is predicted to increase slowly.
Integration with AI and Machine Learning holds immense potential for digital breast tomosynthesis (DBT) equipment manufacturers. By incorporating AI and machine learning algorithms into DBT systems, digital breast tomosynthesis (DBT) equipment manufacturers can significantly enhance the interpretation of breast images. These technologies improve the accuracy of identifying abnormalities, reducing false positives and missed detections.
AI-driven software solutions aid radiologists in streamlining their workflow, making the diagnostic process more efficient. This improves patient outcomes by enabling earlier and more accurate diagnoses and boosts the overall appeal and competitiveness of DBT equipment in the rapidly evolving field of breast cancer screening and diagnosis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The 3-D Equipment section is a prominent digital breast tomosynthesis (DBT) equipment market growth driver within the product type category. Comparing 3-D equipment to conventional 2-D equipment reveals various benefits. In addition to lowering false positives and enhancing early cancer diagnosis, it offers sharper and more detailed images. This cutting-edge technology is becoming increasingly popular with patients and medical professionals for breast cancer screening.
| Leading Segment | 3-D Equipment |
|---|---|
| Segment Share | 62.3% |
The accuracy of 3-D imaging has improved, and there is now less radiation exposure, making it a safer and more effective option. The demand for DBT equipment is increasing as people become more aware of the advantages of breast cancer screening. Regulatory approvals and reimbursement procedures fuel digital breast tomosynthesis (DBT) equipment market expansion. The effectiveness and innovation of the 3-D Equipment category continue to fuel digital breast tomosynthesis equipment market expansion.
The primary end-user category for the digital breast tomosynthesis (DBT) equipment sales is the hospitals segment. Hospitals serve as the key diagnostic and therapeutic hubs for breast cancer, making them the ideal locations for cutting-edge breast imaging technology like DBT. Hospitals frequently have the money to invest in expensive medical technology, ensuring a constant demand for DBT systems.
Since hospitals are multidisciplinary settings, radiologists, oncologists, and surgeons can work together to provide comprehensive breast cancer care that uses the diagnostic accuracy provided by DBT.
| Leading Segment | Hospitals |
|---|---|
| Segment Share | 64.9% |
Hospitals frequently have the infrastructure to provide breast screening and diagnosis under one roof, improving patient care. Patient convenience and accessibility also play a vital role. Due to its congruence with clinical demands and financial capabilities, the hospital segment has attractive sales.
The United States shines out as a significant digital breast tomosynthesis (DBT) equipment market. The United States has a strong healthcare system and a high rate of breast cancer screenings, which drives demand for improved imaging technologies. The United States digital breast tomosynthesis (DBT) equipment market places a high value on technological innovation, creating a competitive environment that stimulates the creation and use of cutting-edge medical technology.
| Attributes | Details |
|---|---|
| Market Share | 45.3% |
The United States has a big population, including an aging population, which raises the importance of early breast cancer detection. Insurance coverage and reimbursement policies encourage DBT use, making therapy more accessible to a broader patient population. The medical research and regulatory organizations in the United States maintain stringent standards, increasing belief in DBT's efficacy and safety and fuelling its market expansion.
The United States is a significant player in the DBT equipment market due to factors including healthcare infrastructure, innovation, demographics, governmental support, and regulatory monitoring.
China is a tremendously profitable digital breast tomosynthesis (DBT) equipment market. China's vast population of around 1.4 billion people translates into a large pool of potential patients, fuelling demand for sophisticated breast cancer screening technologies such as DBT. Rising breast cancer awareness and the necessity of early detection have increased Chinese women's willingness to undergo screenings, strengthening the DBT equipment market.
| Attributes | Details |
|---|---|
| Market CAGR | 11.2% |
The healthcare infrastructure in China is quickly expanding, with an increase in hospitals and diagnostic centers implementing cutting-edge medical technologies. The government's attempts to enhance healthcare access and insurance coverage drive DBT equipment uptake.
China's large population, improved healthcare infrastructure, increased awareness, and rising disposable budgets make it an extremely appealing market for DBT equipment manufacturers.
Due to the rising incidence of breast cancer in India, there is a growing demand for better diagnostic tools, making DBT a key technology for early detection and precise diagnosis. The growing awareness of breast health and the significance of regular screenings among Indian women has spurred the adoption of DBT.
| Attributes | Details |
|---|---|
| Market CAGR | 12.4% |
With a growing middle-class population willing to invest in better healthcare, India's healthcare infrastructure is fast increasing. This, combined with government attempts to enhance healthcare access, creates a favorable atmosphere for DBT equipment manufacturers to prosper. Some firms' reasonable pricing and innovative financing methods make DBT more accessible to a wider range of healthcare facilities, including smaller clinics and hospitals.
India is a potential digital breast tomosynthesis (DBT) equipment market because of the country's expanding healthcare demands, increased awareness, improved infrastructure, and affordability issues.
The digital breast tomosynthesis (DBT) equipment market outlook for the United Kingdom is defined by rising demand for advanced breast imaging technology and a dedication to improving breast cancer detection and diagnosis. DBT, which provides superior imaging capabilities to standard mammography, is gaining traction in the United Kingdom's healthcare industry.
The National Health Service (NHS) has been actively introducing DBT into breast cancer screening programs to increase early detection rates and decrease false positives.
| Attributes | Details |
|---|---|
| Market CAGR | 10.0% |
The United Kingdom's strong research and development ecosystem, which includes cooperation between academia and industry, contributes to DBT equipment innovation and technological breakthroughs. Regulatory authorities such as the Medicines and Healthcare Products Regulatory Agency (MHRA) ensure product safety and efficacy, which increases market trust.
The United Kingdom is projected to have continuous investment and expansion in the DBT equipment market as breast cancer continues to be a leading health concern, providing possibilities for domestic and foreign producers to forge a presence in this changing market.
The digital breast tomosynthesis equipment market is strongly competitive, with many businesses fighting for market share. Leading digital breast tomosynthesis equipment manufacturers use tactics like innovation, research and development investments, and collaborations to preserve their competitive advantage.
New digital breast tomosynthesis (DBT) equipment manufacturers are joining the market with creative solutions, escalating the rivalry and accelerating the development of DBT equipment. The rising demand for breast cancer screening options fuels the digital breast tomosynthesis (DBT) equipment industry's competitive dynamics.
Recent Advancements
| Company | Details |
|---|---|
| Bayer | In January 2023, Bayer said it may buy Blackford Analysis Ltd. to help satisfy the growing demand for medical imaging and the shortage of radiologists. Encouraging innovation in radiology and integrating AI into clinical workflow essentially strives to improve patient quality of life. |
| University College London Hospitals (UCLH) | Initiated by University College London Hospitals (UCLH) in January 2023, the first proton beam therapy trial for breast cancer to more precisely target radiotherapy beams for patients at risk for long-term heart problems. Proton beam therapy can help focus on giving breast tissue the right doses of radiation by reducing off-target radiation to the heart. |
| Whiterabbit | Whiterabbit created the ACT program in August 2022, which uses images of digital breast tomosynthesis, or 3D mammography, to analyze breast cancer automatically. |
| Therapixel | Therapixel secured EUR 15 million in Series B fundraising in May 2022 to increase its commercial footprint in the United States, offer new features for its MammoScreen platform, and push the limits of its reading tool for mammography. |
| Hologic, Inc. | Hologic, Inc. declared the inauguration of its innovation hub in France in March 2022. With the addition of this facility, breast healthcare may benefit from improved ultrasound, interventional, and surgical options. |
| GE Healthcare | GE Healthcare and Unilabs signed a partnership contract in April 2022. GE Healthcare provides X-rays, ultrasound, mammography, and MRI equipment with cutting-edge technology to Unilabs in Portugal. |
The market is to secure a valuation of US$ 2,594.4 million in 2023.
The market is estimated to reach US$ 9495.1 million by 2033.
Through 2033, the industry is anticipated to expand at a 13.9% CAGR.
From 2018 to 2022, the digital breast tomosynthesis equipment market recorded a 15.9% HCAGR.
The 3-D equipment sector is set to achieve a market share of 62.3%.
A 64.9% market share is expected for the hospital sector.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2023 to 2033 5.3.1. 3-D Equipment 5.3.2. 3-D Upgradation 5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Diagnostic Centres 6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. The USA 8.2.1.2. Canada 8.2.2. By Product 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Product 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Product 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By End User 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Product 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By End User 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Product 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By End User 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Product 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Product 13.2.3. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By End User 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Product 14.2.3. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By End User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Product 15.1.2.2. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Product 15.2.2.2. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Product 15.3.2.2. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Product 15.4.2.2. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Product 15.5.2.2. By End User 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Product 15.6.2.2. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Product 15.7.2.2. By End User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Product 15.8.2.2. By End User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Product 15.9.2.2. By End User 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Product 15.10.2.2. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Product 15.11.2.2. By End User 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Product 15.12.2.2. By End User 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Product 15.13.2.2. By End User 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Product 15.14.2.2. By End User 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Product 15.15.2.2. By End User 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Product 15.16.2.2. By End User 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Product 15.17.2.2. By End User 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Product 15.18.2.2. By End User 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Product 15.19.2.2. By End User 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Product 15.20.2.2. By End User 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Product 15.21.2.2. By End User 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Product 15.22.2.2. By End User 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Product 15.23.2.2. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product 16.3.3. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. GE Healthcare 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Siemens Healthineers 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Hologic Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Canon Medical 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. FUJIFILM Holdings Corporation 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. General Electric Company 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Internazionale Medico Scientifica 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. PLANMED OY 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Analogic Corporation 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Trivitron Healthcare 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Digital Breast Tomosynthesis (DBT) Equipment Market
